Cough Characteristics and Healthcare Journeys of Chronic Cough Patients in Community-Based Populations in South Korea and Taiwan.


Journal

Lung
ISSN: 1432-1750
Titre abrégé: Lung
Pays: United States
ID NLM: 7701875

Informations de publication

Date de publication:
12 2022
Historique:
received: 13 09 2022
accepted: 18 10 2022
pubmed: 5 11 2022
medline: 23 11 2022
entrez: 4 11 2022
Statut: ppublish

Résumé

This study aimed to understand the cough characteristics and health journeys among community-based chronic cough (CC) patients, and their characteristics associated with healthcare visits. A population-based cross-sectional study was conducted in 2020, using the South Korea and Taiwan National Health and Wellness Survey (NHWS) and CC surveys. Patients with current CC were defined by daily coughing for > 8 weeks in the past 12 months and currently coughing at the time of survey. The survey items pertained to CC patients' treatment journey and cough characteristics. Patients with current CC in South Korea and Taiwan, respectively, had cough duration for 3.45 ± 5.13 years and 5.75 ± 7.28 years and cough severity visual analogue scale (VAS) scores of 4.50 ± 2.15 and 4.46 ± 1.92 out of 0-10 scale, with 70.3% and 57.9% having spoken with a physician about cough. Compared to CC patients who had not visited healthcare professionals for cough, those who visited reported more severe cough (VAS: 3.89 ± 1.71 vs. 4.6 ± 2.02; p = 0.009), worse cough-specific quality of life (Leicester Cough Questionnaire: 16.20 ± 3.23 vs.13.45 ± 2.68, p < 0.001), greater symptom severity (Hull Airway Reflux Questionnaire: 16.73 ± 15.16 vs. 24.57 ± 13.38; p < 0.001), and more urinary incontinence (13.6 vs. 26.5%, p = 0.027). More than 50% of patients perceived cough medication(s) as not or a little useful and 25% felt their physicians did not well understand how CC impacts their life. Cough is frequently severe and persistent among community-based CC patients. They experience several issues in their health journey, including treatment ineffectiveness and physician's understanding. Further efforts are warranted to reduce CC burden in the community.

Identifiants

pubmed: 36329168
doi: 10.1007/s00408-022-00586-3
pii: 10.1007/s00408-022-00586-3
pmc: PMC9675671
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

725-736

Informations de copyright

© 2022. The Author(s).

Références

Medicine (Baltimore). 2016 Jul;95(27):e3854
pubmed: 27399064
BMJ Open Respir Res. 2021 Mar;8(1):
pubmed: 33785505
J Allergy Clin Immunol Pract. 2022 Jun;10(6):1587-1597
pubmed: 35272071
Allergy Asthma Immunol Res. 2019 Nov;11(6):871-884
pubmed: 31552721
Eur Respir J. 2020 Jan 2;55(1):
pubmed: 31515408
BMJ Open Respir Res. 2021 Jul;8(1):
pubmed: 34266852
Arch Intern Med. 1998 Aug 10-24;158(15):1657-61
pubmed: 9701100
Lung. 2019 Oct;197(5):635-639
pubmed: 31418078
BMC Pulm Med. 2022 Jul 18;22(1):276
pubmed: 35850673
Thorax. 2006 Nov;61(11):975-9
pubmed: 16809412
Allergy Asthma Immunol Res. 2019 Sep;11(5):622-631
pubmed: 31332974
BMC Pulm Med. 2021 Sep 27;21(1):305
pubmed: 34579688
Allergy Asthma Immunol Res. 2016 Mar;8(2):146-55
pubmed: 26739408
Ann Allergy Asthma Immunol. 2022 May 13;:
pubmed: 35569802
Medicine (Baltimore). 2016 Sep;95(37):e4595
pubmed: 27631208
Lung. 2021 Apr;199(2):121-129
pubmed: 33825965
Allergy Asthma Immunol Res. 2018 Nov;10(6):591-613
pubmed: 30306744
Chest. 2018 Jan;153(1):196-209
pubmed: 29080708
ERJ Open Res. 2021 Feb 22;7(1):
pubmed: 33644221
Eur Respir J. 2015 May;45(5):1479-81
pubmed: 25657027
Nat Rev Dis Primers. 2022 Jun 30;8(1):45
pubmed: 35773287
Lung. 2015 Jun;193(3):401-8
pubmed: 25787221
Chest. 2021 Jun;159(6):2346-2355
pubmed: 33345951
Curr Med Res Opin. 2021 Dec;37(12):2175-2184
pubmed: 34543142
World Allergy Organ J. 2022 Sep 05;15(9):100681
pubmed: 36119656
Asia Pac Allergy. 2015 Jul;5(3):136-44
pubmed: 26240790
Lung. 2011 Feb;189(1):73-9
pubmed: 21240613
BMJ Open. 2021 Dec 17;11(12):e054832
pubmed: 34921086
Popul Health Metr. 2016 Nov 5;14:38
pubmed: 27822144
Thorax. 2003 Apr;58(4):339-43
pubmed: 12668799
Am Rev Respir Dis. 1990 Mar;141(3):640-7
pubmed: 2178528
Allergy Asthma Immunol Res. 2020 Nov;12(6):964-979
pubmed: 32935489
Ann Otol Rhinol Laryngol. 2022 Jul 14;:34894221112517
pubmed: 35833581
Eur Respir J. 2004 Sep;24(3):481-92
pubmed: 15358710
ERJ Open Res. 2021 May 04;7(2):
pubmed: 34007841

Auteurs

Woo-Jung Song (WJ)

Department of Allergy and Clinical Immunology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

Chong-Jen Yu (CJ)

Department of Internal Medicine, and Graduate Institute of Clinical Medicine, National Taiwan University Hospital, Hsin-Chu Branch and National Taiwan University College of Medicine, Taipei, Taiwan.

Suk Hyun Kang (SH)

Market Access, MSD, Seoul, Korea. sukhyun.kang@merck.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH